ASSET - AI for Sustainable Prevention of Autoimmunity in the Society
| Reference number | |
| Coordinator | Diamyd Medical AB |
| Funding from Vinnova | SEK 39 702 296 |
| Project duration | September 2021 - September 2026 |
| Status | Ongoing |
| Venture | Innovationsmiljöer inom precisionshälsa |
| Call | Innovation milieus in precision Health 2021 |
Important results from the project
ASSET built a precision-health chain from data to clinic. AI models were developed that estimate the individual time to type 1 diabetes onset, as well as a proposed system for individualised monitoring. The TUPP pilot study tested child-health-centre screening for autoimmune diseases, and DiaPrecise treated individuals with precision medicine. The project created a lasting forum for care, research, patients, authorities and companies. Core goals were met, but some sub-goals were not completed.
Expected long term effects
ASSET can contribute to the development of precision health in Swedish healthcare through individualised identification and monitoring of disease risk using AI. AI support, pilot studies and collaboration provide a basis for the continued development of organised screening, highlight possible synergies and efficiencies, and improve the conditions for preventive action. Over time this may prevent and reduce the severe consequences of disease and lower costs for society.
Approach and implementation
ASSET brought together companies, academia and healthcare around data, clinical pilots and healthcare conditions. TEDDY data were used to develop AI-based risk models. TUPP tested child-health-centre sampling and DiaPrecise tested targeted immunotherapy before onset. Recurring conferences and round-tables gathered patients, care, researchers, authorities and companies. The learnings were summarised in the dialogue material “Framtidens screening”. A steering group supported the work throughout.